89zr-gsk2849330
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 19, 2015 (NCT02345174)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor tyrosine-protein kinase erbB-3Immunity, passive
ERBB3 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 89-Zirconium
Oral
No
Parenteral
No
Topical
No
Also known as
- 89zr-gsk2849330
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02345174 | Phase 1 | Mar 19, 2015 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1